Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
A long-term British study revealed that there are correlations between childhood TV viewing time and adult TV viewing time….
Read More »Monthly Archives: September 2014
The Effectiveness of Different Diet Programs on Weight Loss
Weight loss outcomes are comparable among named diet programs….
Read More »Vagal Nerve Blockade for Obesity Treatment
Vagal nerve blockade might not be an effective therapy for obesity treatment….
Read More »Overall Dietary Quality in the U.S Remains Poor
Better dietary quality links to higher socioeconomic status….
Read More »Editor’s Note, DCMS #206
When Al Mann first said he was going to develop an inhaled insulin, many thought he was beating a dead horse after the collective experiences with Exubera. They forgot that Al had already built the most successful pump company of all times, and that he did not like to fail. …
Read More »IDF Diabetes Atlas – North America and Caribbean
Diabetes is a huge and growing problem, and the costs to society are high and escalating. More was spent in 2013 in North America and the Caribbean than in any other region. The Top 5 countries for prevalence in North America and the Caribbean are: Belize, Guyana, Curacao, Martinique, and …
Read More »Afrezza – Dreamboat Inhaler and Cartridge
With this week’s Homerun Slides, we have a short special presentation for you on the new inhaled insulin, Afrezza, that goes with our exclusive interview by our publisher, Steve Freed, with the founder and CEO of Mannkind Corp, Al Mann….
Read More »An Exclusive Interview with Al Mann, Founder and CEO, Mannkind Corp.
This week, we are taking a break from our Clinical Text presentations, to bring you this exclusive interview with Al Mann, the legendary founder of Mannkind Corp, and the person primarily responsible for backing the development of the inhaled insulin product, Afrezza, soon to be on the market. Steve Freed: …
Read More »Editor’s Note, SGLT-2 Inhibitor Special Edition, September 2014
As new medications for diabetes come to market there is always a question as to how well they will work when added to other medications. This month, we have a slide presentation from the ADA, outlining the rationale for mating DPP-4 inhibitors with SGLT-2 inhibitors.
Read More »SGLT2 Inhibitors as Add-On for Poorly Controlled Patients on DPP-4s and Metformin
As the diabetes epidemic continues to grow, practitioners are increasingly searching for medication solutions that can help patients to better manage their diabetes. This month, we have a recent slides series from the ADA showing the positive effects of adding-on SGLT-2 inhibitors to the medication regimen of patients on DPP-4’s …
Read More »